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Among 128 patients routinely receiving highly active
antiretroviral therapy in an HIV/AIDS outpatient clinic in
Cameroon, 16.4% had drug resistance after a median of 10
months. Of these, 12.5% had resistance to nucleoside
reverse transcriptase inhibitors (NRTIs), 10.2% to non-
NRTIs, and 2.3% to protease inhibitors. 
H
IV drug resistance is a major threat to the scaling up
of antiretroviral therapy (ART) in developing coun-
tries (the World Health Organization/United Nations
Programme on HIV/AIDS “3 by 5” Initiative) (1), espe-
cially in Africa (2). Inadequate clinical and biological fol-
low-up has been linked to high rates of drug resistance
(>50% after 8 to 20 months) in Gabon (3), Côte d’Ivoire
(4), and Uganda (5). In a recent study in public and private
health care clinics in Douala, the economic capital of
Cameroon, we found that the clinical and biological fol-
low-up and drug supply were irregular and that many
patients interrupted their treatment (6). Data on drug resist-
ance in the routine care setting are urgently required to
design large, effective ART programs. We describe the fre-
quency and nature of major genotypic mutations confer-
ring resistance to antiretroviral drugs among patients
treated in a routine HIV/AIDS outpatient clinic in
Yaoundé, the political capital of Cameroon.
The Study
We conducted a cross-sectional survey from January
2002 to January 2004 among HIV-1–infected patients
managed at the Central Hospital. The patients had to pay
for their drugs (US $23–$100 monthly) and laboratory
tests (US $58–$85 per viral load assay and $19–$27 per
CD4 cell count). Consequently, follow-up was often irreg-
ular. All patients who were given ART for at least 3 months
were eligible for the study. Approximately 15%–20% of
eligible patients refused or were not asked (physicians for-
got) to participate. Blood samples were not available for 9
other patients. The Cameroon national ethics committee
approved the study protocol, and patients gave their
informed consent. Basic demographic and medical data
were recorded on a standard questionnaire.
HIV was typed in each patient (HIV-1 group M, N, or
O, or HIV-2) with an in-house enzyme-linked immunosor-
bent assay (ELISA) based on V3 loop peptides (7).
Genotypic resistance to antiretroviral drugs was studied by
sequencing the protease and reverse transcriptase genes
with group M- or O-specific primers, depending on the
serotyping results (8); samples that could not be typed with
ELISA were tested with both group M and O primers.
Briefly, viral RNA was extracted from plasma with the
QIAamp Viral RNA minikit (Qiagen, Courtaboeuf,
France) and reverse transcribed to cDNAby using Expand
RT (Boehringer, Mannheim, Germany) and a reverse
primer. An 1,800-bp fragment encompassing the protease
and reverse transcriptase genes was amplified by nested
polymerase chain reaction and directly sequenced with an
ABI PrISM Big Dye Terminator cycle sequencing ready
reaction kit (Perkin-Elmer, Roissy, France). Genetic sub-
types were determined by phylogenetic tree analysis with
the Clustal W program (8). The deduced amino acid
sequences were compared with a reference sequence to
detect mutations associated with resistance. Mutations
were classified as minor or major, by using the September
2004 version of the French National Agency for Research
on AIDS consensus statements on antiretroviral drug
resistance (http://www.hivfrenchresistance.org). A suscep-
tible strain based on absence of major drug resistance
mutations by genotyping or a strain that could not be
amplified for genotyping was considered nonresistant.
One hundred twenty-eight HIV-1–infected patients
received ART for a median of 10 months (interquartile
range [IQR] 7–18). Median age was 39 years (IQR 33–46);
70 (54.7%) of the patients were women. In addition to
nucleoside reverse transcriptase inhibitors (NRTIs), 94
patients (73.4%) had received non-NRTIs (59 patients
received only efavirenz, 30 received only nevirapine, and
5 received both) and 53 patients (41.4%) had received pro-
tease inhibitors (PIs, 50 patients received only indinavir, 2
received only nelfinavir, and l received both); 19 patients
had received both non-NRTIs and PIs. Two patients (1.6%)
initially received only 2 NRTIs (lamivudine and zidovu-
dine for 7 months in 1 case; stavudine and didanosine for
14 months in the other). Samples from 113 patients
(88.3%) reacted with group M peptides, 3 samples (2.3%)
reacted with group O peptides, and 2 other samples (1.6%)
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Thirty-five samples could be amplified, and all were char-
acterized in the pol gene. The circulating recombinant
form (CRF) 02-AG strain predominated (22 patients,
62.9%); the other 13 patients had subtype A (1), D (2) or
F2 (3), or CRF01-AE (2), CRF02-AG/F (2), CRF11-cpx
(2), or CRF13-cpx (1).
Major genotypic mutations associated with antiretrovi-
ral drugs resistance were detected in 21 patients (16.4%,
95% confidence interval 10.5–24.0). The characteristics of
these patients are shown in the Table. Sixteen patients
(12.5%) had resistance to NRTIs (Figure) due to the muta-
tions M184V (15 patients), M184I (1), T215Y (1), T215F
(3), K65R (2), and Q151M (1); thymidine analog muta-
tions M41L (2), D67N (2), K70R (3), K219Q (1), and
K219E (1) were also detected. Thirteen patients (10.2%)
had resistance to non-NRTIs due to the mutations K103N
(11), K101E (1), Y181C (1), Y188L (2), G190E (1), and
P225H (2). Three patients (2.3%) had resistance to PIs due
to the mutations V82A (2 patients) and N88D (1). The 2
patients treated for a time with only 2 NRTIs (patients 2-
59 and 2-84, Table) had several major genotypic mutations
but had received ART for 52 and 48 months, respectively. 
Conclusions
This observational study showed that 16.4% of patients
receiving ART in a routine care setting in Cameroon had
drug resistance after a median of 10 months. The rate of
resistance was lower than that observed in earlier studies in
Côte d’Ivoire (4), Gabon (3), and Uganda (5). Several fac-
tors could explain this finding. First, a history of subopti-
mal therapy was rare: only 2 patients had received a 2-drug
regimen, and none had received single-agent therapy.
Second, 90% of our patients began receiving ART after a
national consensus conference held in June 2000 had stan-
dardized the drugs supply, drugs regimen, and clinical and
biological follow-up. Third, the physicians were trained
and experienced in ART use. Fourth, the cost of drugs and
laboratory tests has fallen in recent years in Cameroon, a
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also account for the difference: our median follow-up peri-
od was substantially less than that in the studies in Gabon
and Uganda, so that our patients had less time for resist-
ance to develop, and our assumption that nonamplification
was equivalent to nonresistance could have led to an
undercount of resistant strains. Lower rates of resistance
were achieved in pilot studies in Cameroon (9) and
Senegal (10,11), thanks to measures favoring adherence to
therapy, such as provision of drugs and laboratory follow-
up at no cost (or for a limited charge), and psychosocial
support (counseling, access to discussion groups, and
active search for patients who did not attend scheduled
clinical visits, biological examinations, or drug dispensing
sessions).
Resistance most often involved lamivudine (12.5%;
and emtricitabine, due to mutation M184V/I related to
lamivudine pressure [emtricitabine was not used in
Cameroon]), efavirenz, and nevirapine (10.2%). These
drugs are widely used in Cameroon in either individual
formulations or fixed-dose combinations (lamivudine/
zidovudine, lamivudine/stavudine, lamivudine/stavudine/
nevirapine, and lamivudine/zidovudine/nevirapine). The
fixed-dose combination of lamivudine/stavudine/nevirap-
ine is now the most frequently prescribed drug in
Cameroon and other African countries (12). In our study,
19 patients (14.8%) had resistance to >1 component on this
fixed-dose combination, and high rates of resistance could
compromise the use of this inexpensive (US $4.5 monthly)
and convenient drug. Frequent resistance to nevirapine
could also compromise the use of this drug for preventing
mother-child transmission (most such programs in Africa,
including in Cameroon, are based on nevirapine).
Our study showed a relatively low level of resistance
after a median duration of 10 months’ treatment in a rou-
tine care setting, but we could not evaluate the association
of resistance with adherence, support, or prescribing prac-
tices. The differences in methods among the African cross-
sectional studies of resistance, including our own and the
others referenced, make comparisons among countries dif-
ficult, although some differences are likely due to prescrib-
ing practices, drug availability, support for adherence, and
follow-up. More extensive prospective studies that use
standardized methods could provide comparable estimates
of resistance seen at specific times (e.g., 6, 12, and 24
months after ART begins) in different countries and delin-
eate ART program factors associated with a low preva-
lence of resistance.
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